Writing Group Disclosures.
| Writing Group Member |
Employment | Research Grant | Other Research Support |
Speakers’ Bureau/ Honoraria |
Expert Witness |
Ownership Interest |
Consultant/ Advisory Board |
Other |
|---|---|---|---|---|---|---|---|---|
| Leslee J. Shaw | Emory University | None | None | None | None | None | None | None |
| Marcelo F. Di Carli | Brigham & Women’s Hospital | Spectrum Dynamics* | None | None | None | None | None | None |
| Rob S.B. Beanlands | University of Ottawa Heart Institute Cardiology | JubilantDraxImage†; Lantheus Medical Imaging† | None | None | None | None | JubilantDraxImage*; Lantheus Medical Imaging*; KAI Research* | None |
| Ron Blankstein | Brigham & Women’s Hospital | Amgen* | None | None | None | None | EKOS, Inc*; Amgen, Inc* | None |
| Scott D. Flamm | Cleveland Clinic Imaging Institute | None | None | None | None | Precision Image Analysis*; Arterys* | Precision Image Analysis*; Arterys* | None |
| Thomas C. Gerber | Mayo Clinic | None | None | None | None | None | None | None |
| Jill E. Jacobs | NYU Langone Medical Center | None | None | None | None | None | None | None |
| Raymond Y. Kwong | Brigham & Women’s Hospital | None | None | None | None | None | None | None |
| Jonathon A. Leipsic | University of British Columbia | None | Medtronic†; Neovasc†; Tendyne† | GE Healthcare*; Samsung* | None | PI Cardia*; eartflow† | Circle†; Edwards*; Heartflow† | None |
| Jennifer H. Mieres | Northwell Health Cardiology | None | None | None | None | None | None | None |
| John Spertus | Saint Luke’s Mid America Heart Institute | None | None | None | None | None | None | None |
| Viviany R. Taqueti | Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.